Thanks to Merck & Co. Inc.'s earnings report Wednesday, we now know the 2007 sales of Vytorin and Zetia, the drugs at the center of the latest episode to roil the pharmaceutical industry.
Merck/Schering-Plough Pharmaceuticals recorded sales of $2.78 billion for Vytorin in 2007 compared with $1.96 billion in 2006. Sales of Zetia were $2.41 billion in 2007 vs. $1.93 billion the previous year.
